Why the Facility of the Year Awards are Important to Pharma Industry
ISPE’s Facility of the Year Awards (FOYA) program recognizes the shared commitment and dedication of companies worldwide, to enhance patient health and safety through innovation and advancement.
“The FOYA Award is important [to the] industry as a whole because it provides a platform to share knowledge and experience,” said Ryan Hawkins, Vice President and Chief Operating Officer, Cook Pharmica, LLC, 2017 FOYA Category Winner for Equipment Innovation.
“If you think about it, where else can you get that type of snapshot of major projects, of major technological advances in [the] industry, [and it] also says a lot about the importance of the FOYA awards,” said Hawkins.
Christopher Sweeney, Senior General Manager, Pt Kalbio Global Medika, 2017 FOYA Honorable Mention shared, “The reason why we joined the FOYA awards was that we’re very proud of our facility and we wanted to show the industry that in Indonesia, we can build the equivalent, or even better of some of the facilities in the West.”
The Facility of the Year Awards category winners represent the epitome of companies who utilize pioneering technology and design to help set the standard for future pharmaceutical facilities.
“We really felt that [it] was a vindication of our design and our hard work, and it gave confidence to the parent company to expand our operations,” said Sweeney.
“Being a winner of the FOYA award, and being worthy of that distinction, means a lot,” said Hawkins. “What it means, is we’re becoming operational, and with the purpose of serving more customers and therefore more patients.”
The 2017 FOYA Facility of the Future and Overall Winner was awarded to Eli Lilly and Company. “[We] appreciate ISPE for leading the industry towards where we want to go,” said David Sternasty, Vice President of Corporate Engineering and Global Health, Safety and Environment.
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...